ArticleIranian journal of pathology2015
Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma.
Article in Iranian journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Identification of distinct profiles of glioblastoma through the immunocapture of extracellular vesicles from patient plasma.PloS one · 2025Article
- Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide.Acta oncologica (Stockholm, Sweden) · 2024Article
- Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression.International journal of molecular sciences · 2024Article
- Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit fromFrontiers in neuroscience · 2023Article
- CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Human Adipose-Derived Stem Cell-Conditioned Medium Promotes Vascularization of Nanostructured Scaffold Transplanted into Nude Mice.Nanomaterials (Basel, Switzerland) · 2022Article
- Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy.Frontiers in oncology · 2022Article
- Advances in immunotherapy and molecular targeted therapy of gestational trophoblastic tumor: current practice and future perspectives.American journal of cancer research · 2022Review
- The low affinity A2B adenosine receptor enhances migratory and invasive capacityFrontiers in oncology · 2022Article
- Article
- A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.Cancers · 2021Review
- Article
- Evaluation of Nestin and EGFR in Patients with Glioblastoma Multiforme in a Public Hospital in Iran.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- A comparison of CD105 and CD31 expression in tumor vessels of hepatocellular carcinoma by tissue microarray and flow cytometry.Experimental and therapeutic medicine · 2018Article
- Article
- Assessment of Micro-vessel Density in Brain Gliomaby CD105 Expression.Iranian journal of pathology · 2018Article
- Overexpression and correlation of HIF-2α, VEGFA and EphA2 in residual hepatocellular carcinoma following high-intensity focused ultrasound treatment: Implications for tumor recurrence and progression.Experimental and therapeutic medicine · 2017Article
- Immunohistochemical Comparison of the Expression of CD34 and CD105 in Odontogenic Keratocyst and Dentigerous Cyst.Journal of dentistry (Shiraz, Iran) · 2017Article
- Distinct role of heme oxygenase-1 in early- and late-stage intracerebral hemorrhage in 12-month-old mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAngiogenesis is essential for growth and metastasis of solid malignancies. Tumor vessel count and expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, have been associated with prognosis. This study was designed to assess vessels density by using CD31 and CD105 (Endoglin) and their correlation with expression of VEGF and proliferative index (Ki67) in Glioblastoma multiforme (GBM).
methodsWe examined these parameters in GBM specimens from 50 adult patients; referred to Al-Zahra hospital Pathology Lab between 2001 to 2006.These patients did not receive pre-operative therapy. Paraffin-embedded tumor specimens were immunohistochemically stained for CD31, CD105 (Endoglin), VEGF and Ki67 (proliferation index) monoclonal antibodies. Microvessel density (MVD) was evaluated by immunostaining for CD31 and CD105.Then the results were compared between the two and also with VEGF receptors and Ki67 index.
resultsCD105-MVD was significantly higher in Glioblastoma compared with peritumoral normal (14.28 vs. 6.68: P=0.012). We did not find such difference for CD31. The mean of CD105-MVD was significantly higher than CD31-MVD in Glioblastoma tissue (P<0.001) although there was a significant positive relationship between them (Pearson's r=0.630 P<0.001).The VEGF scoring for tumoral tissue was 12 % (score:1), 46% (score:2) and 42% (score:3).For peritumoral normal tissue were 92% (score:1) and 8% (score:2) . So they reach to statistical significance (Chi Square, P = 0001). Both MVD of CD105 and CD31 have significant relationship with VEGF (P<0.001).
conclusionWe suggest that Endoglin can be used as a specific and sensitive marker for evaluation of angiogenesis in Glioblastoma.
Indexed as
Identifiers
26351468PMC4539765W1908539276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.